<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00652444</url>
  </required_header>
  <id_info>
    <org_study_id>0653-151</org_study_id>
    <secondary_id>2008_004</secondary_id>
    <nct_id>NCT00652444</nct_id>
  </id_info>
  <brief_title>Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial (0653-151)</brief_title>
  <official_title>Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The primary outcome was percentage reduction of LDL-C after 6 weeks of randomization.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage reduction of LDL-C after 6 weeks of treatment.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Coadministration arm: simvastatin 20mg and ezetimibe 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy arm: simvastatin 20mg and ezetimibe placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe</intervention_name>
    <description>ezetimibe 10mg. Blood samples were collected again at the end of study treatment, week 6.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zetia®</other_name>
    <other_name>EZETROL®</other_name>
    <other_name>MK0653</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>simvastatin 20mg . Blood samples were collected again at the end of study treatment, week 6.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Zocor®</other_name>
    <other_name>MK0733</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Unspecified)</intervention_name>
    <description>Matching ezetimibe placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with known Coronary Artery Disease (CAD) and primary hypercholesterolemia,
             who are being treated with simvastatin 20mg. Simvastatin consumption meant that
             subjects must be currently taking simvastatin 20mg daily, and by history have taken at
             least 80% of daily evening doses for the preceding 6 weeks prior to baseline visit

          -  Age of at least 18 years and 75 years or less

          -  Calculated LDL-C concentration of at least 2.6 and 4.1mmol/l or less using the
             Friedewald equation, and triglyceride of less than 3.99 mmol/l

        Exclusion Criteria:

          -  Congestive heart failure (defined as New York Heart Association class III or IV heart
             failure)

          -  Uncontrolled cardiac arrhythmias

          -  Acute coronary syndrome, coronary bypass surgery or coronary angioplasty within 3
             months of study entry

          -  History of unstable or severe peripheral artery disease within 3 months of study entry

          -  Uncontrolled hypertension at study entry

          -  Uncontrolled or newly diagnosed diabetes mellitus (within 3 months of study entry)

          -  Uncontrolled endocrine or metabolic diseases known to influence serum lipids and
             lipoproteins; known impairment of renal function

          -  Active or chronic hepatic and hepatobiliary disease

          -  Disorders that would limit study evaluation or participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <reference>
    <citation>Zubaid M, Shakir DK, Bazargani N, Binbrek A, Gopal R, Al-Tamimi O, Bakir S. Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial. J Cardiovasc Med (Hagerstown). 2008 Jul;9(7):688-93. doi: 10.2459/JCM.0b013e3282f3a1b1.</citation>
    <PMID>18545068</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2008</study_first_posted>
  <last_update_submitted>January 21, 2016</last_update_submitted>
  <last_update_submitted_qc>January 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

